Ultragenyx Pharma (RARE) Misses Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Wedbush Assumes Ultragenyx Pharma (RARE) at Outperform
February 17, 2017 12:09 PM ESTWedbush assumed coverage on Ultragenyx Pharma (NASDAQ: RARE) with an Outperform rating and a price target of $88.00.
For an analyst ratings summary and ratings history on Ultragenyx Pharma click here. For more ratings news on Ultragenyx Pharma click here.
Shares of Ultragenyx Pharma closed at $76.82 yesterday.
... MoreJefferies Reiterates Buy Rating and $109 PT on Ultragenyx (RARE) Following 'Uneventful' 4Q16 Results
February 17, 2017 8:13 AM ESTJefferies analyst Gena Wang reiterates Buy rating and $109 price target on Ultragenyx Pharmaceuticals (NASDAQ: RARE), noting clinical progress across multiple initiatives, despite an "uneventful" 2016 fourth quarter earnings call, as the company is expecting first commercial product by the end of 2017.
Wang comments, "RARE 4Q16 EC was largely... More
